NCT06047977 - Tumor Infiltrating Lymphocyte Therapy for Pediatric High Risk Solid Tumors | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

June 2, 2025

Primary Completion Date

December 1, 2026

Study Completion Date

December 1, 2027

Conditions

Lymphocytes

Interventions

BIOLOGICAL

Tumor Infiltrating Lymphocytes, Fludarabine, Cyclophosphamide, Interleukin-2

Lymphodepleting Chemotherapy with Fludarabine/Cyclophosphamide followed by TIL and Post-TIL Interleukin-2 (IL-2)

Trial Locations (1)

RECRUITING

Johns Hopkins All Children's Hospital, St. Petersburg

All Listed Sponsors

collaborator

Swim Across America

OTHER

collaborator

Benjamin Gilkey Fund

UNKNOWN

collaborator

Cannonball Kids' Cancer Foundation

OTHER

lead

H. Lee Moffitt Cancer Center and Research Institute

OTHER